MedTrace Logo

Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension

NCT02480764 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 612

Last updated 2019-03-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the antihypertensive effect of azilsartan medoxomil compared with valsartan in Chinese participants with essential hypertension.

Conditions

  • Essential Hypertension

Interventions

DRUG

Azilsartan medoxomil

Azilsartan medoxomil tablets

DRUG

Valsartan

Valsartan 80 mg capsules

DRUG

Azilsartan medoxomil Placebo

Azilsartan medoxomil placebo-matching tablets

DRUG

Valsartan Placebo

Valsartan placebo-matching capsules

Sponsors & Collaborators

Principal Investigators

  • Medical Director Clinical Science · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-27
Primary Completion
2017-09-22
Completion
2017-10-13

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02480764 on ClinicalTrials.gov